
India

REDUCE (no change)

Consensus ratings*: Buy 24	Hold 6	Sell 3
Current price:		Rs2,423
Target price:		Rs1,540
Previous target:		Rs1,540
Up/downside:		-36.4%
InCred Research / Consensus:		-37.6%
Reuters:	5	SRFL.NS
Bloomberg:		SRF IN
Market cap:	US	\$8,614m
	Rs7	'18,267m
Average daily turnover:	U	S\$15.1m
	Rs	1256.8m
Current shares o/s:		296.4m
Free float: *Source: Bloomberg		49.2%



	701
Promoter & Promoter Group	į
Amansa holdings	
Kotak India	

5.8 4.8

SRF Limited

Cut our EPS estimates; retain REDUCE

- The slowdown in the agrochemicals sector and headwinds on the HFC consumption front in the US are leading to sub-par export performance of SRF.
- At the same time, BOPP and PET films demand and profitability, driven by Covid-led disruption, are now falling and may settle down at lower levels.
- We cut our FY24F/25F/26F EPS to Rs47.9/Rs55/Rs66.6, respectively. Retain our REDUCE rating on the stock with a 12-month target price of Rs1,540.

Agrochemical intermediates as well as HFC exports are falling

As pointed out in our earlier report, (IN: Chemicals - Others - Agrochemicals - channel inventory too high), global agrochemicals channel inventory appears to be higher than normal by at least 30%. As per our estimates, it may take 12-18 months to stabilize. After that as well, unlike what happened post-Covid and contrary to street belief, the chemicals segment will not grow at a 20% CAGR. The global agrochemicals market is 90% generic and is growing at 1-2% (in USD terms, Covid-led channel stocking was an anomaly) and hence, in INR terms, the growth in the chemical segment's revenue is unlikely to exceed 8-10%. On the other hand, HFC prices exploded (driven by anti-dumping duty on Chinese imports by the US), which led the chemical segment's margins to exceed 37%, are now falling and will settle way below their historical mean levels. Please note that beginning 2024, the US will cut HFC consumption (IN: Chemicals - Overall - R-125 & R-134A bull run is closer to its end) by 33% (in terms of GWP or global warming potential), which means there will be a structural decline in the volume as well as the prices of high-GWP refrigerants like HFC-125, HFC-22 and HFC-410A. The same is happening now and, in our view, will get accentuated in the coming months.

Consensus EPS estimates need a massive cut

Based on BOPP/ PET margins, current HFC prices and export trajectory, we believe that SRF will do great if it can clock an EPS of more than Rs10 in 3QFY24F. In the most likely case, EPS will be around Rs8.8 for the quarter. We don't find any new molecule in SRF's portfolio that can add significant growth to the company' revenue. Consensus EPS estimates need to be cut by 10% for FY24F and at least by 30% each for FY25F and FY26F.

We cut our below consensus EPS estimates; retain REDUCE rating

We cut FY24F/25F/26F EPS to Rs47.9/Rs55/Rs66.6, respectively. We retain our REDUCE on the stock with a 12-month target price of Rs1,540. Relative to disappointment, SRF's underperformance has not been that big in the last 12 months. The stock is in for a derating as well as EPS cuts, leading to a bigger underperformance in the coming quarters. Upside risk: A sudden recovery in refrigerant prices.

Financial Summary	Mar-22A	Mar-23A	Mar-24F	Mar-25F	Mar-26F
Revenue (Rsm)	124,337	148,703	135,264	139,344	148,146
Operating EBITDA (Rsm)	31,759	35,292	25,786	29,328	33,680
Net Profit (Rsm)	18,889	21,623	14,212	16,293	19,159
Core EPS (Rs)	63.7	73.0	47.9	55.0	64.6
Core EPS Growth	57.6%	14.5%	(34.3%)	14.6%	17.6%
FD Core P/E (x)	38.02	33.21	50.54	44.08	37.49
DPS (Rs)	5.6	6.4	6.4	6.4	6.4
Dividend Yield	0.23%	0.26%	0.26%	0.26%	0.26%
EV/EBITDA (x)	23.48	21.27	28.66	24.85	21.24
P/FCFE (x)	107.97	119.67	73.86	51.13	42.76
Net Gearing	32.3%	31.4%	18.1%	8.1%	(1.9%)
P/BV (x)	8.39	6.95	6.21	5.53	4.88
ROE	24.5%	22.9%	13.0%	13.3%	13.8%
% Change In Core EPS Estimates			(0.23%)	(0.12%)	0.04%
InCred Research/Consensus EPS (x)					

Research Analyst(s)



Satish KUMAR T (91) 22 4161 1562 E satish.kumar@incredresearch.com Abbas PUNJANI T (91) 22 4161 1598 E abbas.punjani@incredresearch.com

Cut our EPS estimates; retain REDUCE

We cut our EPS estimates for FY24F, FY25F and FY26F. 3QFY24F EPS of SRF is likely to be around Rs9, which make consensus earnings estimates totally out of reality. Most likely the FY24F EPS of SRF will be Rs47, which is 25% below the consensus EPS estimate.

BOPP and PET film profits have peaked and they will trend downwards

BOPP is oversupplied in the global market >

Against the global demand for 8mt, the installed BOPP film capacity is 10mt. The commodity is super easy to manufacture as most manufacturers buy polypropylene (PP) from petrochemical manufacturers. These PP chips are melted and pulled to form films of various thickness. The key for any manufacturer is to reduce the wastage in cutting films in different widths (In industry terms, it's called deckle matching).


One of the main usages of BOPP is in food packaging, labelling and making tapes ➤

BOPP films are highly versatile materials used in various applications, with the global consumption touching nearly 8mt in 2022. Key applications of BOPP films are in:

- **Food packaging**: BOPP films are widely used in food packaging due to their excellent barrier properties, preventing moisture, oxygen, and contaminants from reaching the food item.
- **Labelling:** BOPP films are ideal for labels due to their high printing quality, durability, and resistance to chemicals and abrasion.
- **Tapes:** BOPP films are used in various types of tapes, including packaging tapes, electrical tapes, and masking tapes.
- **Industrial lamination**: BOPP films are used for laminating various materials, such as paper, cardboard, and textiles, to improve their strength, durability, and appearance.


The Covid-19 pandemic led to higher demand for BOPP films >

As the Covid-19 pandemic led to global lockouts and people became afraid to venture out, online sales boomed. As a result, there was a higher need for packaging, which led to a higher demand for all packaging products, be it BOPP or PET film.




Consequently, BOPP film prices rose and spreads exploded ➤

Being an oversupplied commodity, things are reverting to their mean. Please note that the mean itself is overstated because of extreme profitability during the Covid-19 pandemic period.



PET films are facing a similar trend>

Given similar usage like that that BOPP films, PET films are also showing the same trend.



PET film, or polyethylene terephthalate film, is a versatile material with a wide range of uses:

Flexible packaging: PET film is commonly used for food and beverage packaging due to its excellent clarity, barrier properties against moisture, oxygen, and aroma, and resistance to chemicals and oils. It is used in products like snack bags, pouches, blister packs, and trays. PET film is used for food packaging.

Labelling: PET film is used for various labels, including product labels, pressuresensitive labels, and shrink sleeves. It offers good printability and durability.

Blister packs: PET film is used to create clear, rigid blister packs for pharmaceuticals, cosmetics, and other consumer goods.

Capacitors: PET film is used as a dielectric material in capacitors due to its high dielectric constant and good electrical insulating properties.

Flexible printed circuits: PET film can be used as the substrate for flexible printed circuits (FPCs) used in various electronic devices, including smartphones, tablets, and wearables.

Touchscreens: PET film coated with a conductive layer is used in touchscreens for smartphones, tablets, and other devices.

Magnetic tape: PET film is used as the backing material for magnetic tape used in audio and video recording.

Industrial laminate: PET film can be used to laminate paper, cardboard, and other materials for increased stiffness, durability, and water resistance.


Insulation: PET film is used as an electrical insulator in various applications, such as wire and cable insulation.

Protective film: PET film is used as a temporary protective film for surfaces during manufacturing and transportation.

Hey days of HFC are over


Supply chain shortage and anti-dumping duty led to higher HFC prices in US. Please note that Indian companies mostly export their products to the US and hence, higher US prices led to sky-high prices of HFC in the past few months. However, the supply chain has stabilized and at the same time the US is reducing HFC consumption, in terms of GWP (global warming potential), by 33%, beginning in 2024. All this is leading to a decline in Indian export prices as well as volume.






It is worth noting that rising HFC-125 prices and good export demand were the only reasons behind SRF posting a 37% EBIT margin in the chemical segment.


R-22 prices have also fallen and similar is the case with its spreads>




India's overall chemicals exports are falling rapidly



Agrochemical customers like Syngenta and Bayer are not buying much ➤



Exports to BASF are also falling rapidly >



The fall in exports to agrochemical cutomers appears to be driven by high inventory in the channel >

Global agrochemical sales in CY22 were up by ~20% (Source: FMC analyst day presentation). Going by UPL and other generic companies' results presentations for FY23, it appears that out of the 20%, half of the growth was driven by volume and the other half by higher prices. This means global channel inventory is overstocked by US\$6bn in volume terms (at CY21 price level). At the same time, as per the commentaries of generic agrochemical makers, the prices are reverting to CY21 levels. Going by the balance sheet of different companies, it appears that channel inventory remains at around four months, or around US\$20bn of agrichemicals remain in the channel. Now, as it's overstocked by US\$6bn, it means channel inventory is higher by 30%. A part of this overstocked inventory is already getting destocked but, in our view, it will take 12 more months for inventory normalization.

We expect an earnings cut post 3QFY24F results


Our earnings estimate for 3QFY24F stands at Rs8.8.

(Rsm)	1QFY23	2QFY23	3QFY23	4QFY23	1QFY24	2QFY24	3QFY24F
Net Revenue	38,947	37,278	34,697	37,781	33,384	31,774	30,056
Expenses							
Total Cost of Goods Sold	18,578	19,529	16,944	18,884	17,005	16,201	15,325
Employee Benefit Expenses	1,942	1,953	2,102	2,142	2,180	2,266	2,266
Power & Fuel Expenses	4,103	3,737	3,443	3,440	3,528	3,438	3,438
Other Expenses	4,126	4,007	3,723	3,719	3,471	3,416	3,416
Total Expenses	28,749	29,226	26,211	28,185	26,184	25,320	24,445
EBITDA	10,198	8,052	8,486	9,596	7,200	6,453	5,612
Depreciation	1,307	1,393	1,507	1,546	1,566	1,612	1,612
EBIT	8,891	6,659	6,979	8,050	5,634	4,841	3,999
Other Income	99	327	100	223	118	291	291
Forex (Gain) /Loss	249	361	150	280	237	191	0
Interest Expense	325	445	620	659	656	793	793
Profit Before Tax	8,416	6,181	6,309	7,334	4,858	4,148	3,498
Other Tax Expenses							
Total Tax Expenses	2,336	1,371	1,200	1,709	1,265	1,140	881
Profit After Tax	6,080	4,810	5,109	5,625	3,593	3,008	2,616
EPS	20.5	16.2	17.2	19.0	12.1	10.2	8.8

InCred Equities

Chemicals - Overall | India SRF Limited | December 11, 2023

BY THE NUMBERS



Profit & Loss

(Rs mn)	Mar-22A	Mar-23A	Mar-24F	Mar-25F	Mar-26F
Total Net Revenues	124,337	148,703	135,264	139,344	148,146
Gross Profit	124,337	148,703	135,264	139,344	148,146
Operating EBITDA	31,759	35,292	25,786	29,328	33,680
Depreciation And Amortisation	(5,172)	(5,753)	(5,702)	(6,587)	(7,107)
Operating EBIT	26,587	29,539	20,084	22,741	26,572
Financial Income/(Expense)	(1,159)	(2,048)	(1,834)	(1,708)	(1,708)
Pretax Income/(Loss) from Assoc.					
Non-Operating Income/(Expense)	428	749	749	749	749
Profit Before Tax (pre-El)	25,856	28,240	19,000	21,782	25,613
Exceptional Items					
Pre-tax Profit	25,856	28,240	19,000	21,782	25,613
Taxation	(6,966)	(6,617)	(4,788)	(5,489)	(6,455)
Exceptional Income - post-tax					
Profit After Tax	18,889	21,623	14,212	16,293	19,159
Minority Interests					
Preferred Dividends					
FX Gain/(Loss) - post tax					
Other Adjustments - post-tax					
Net Profit	18,889	21,623	14,212	16,293	19,159
Recurring Net Profit	18,889	21,623	14,212	16,293	19,159
Fully Diluted Recurring Net Profit	18,889	21,623	14,212	16,293	19,159

Cash Flow					
(Rs mn)	Mar-22A	Mar-23A	Mar-24F	Mar-25F	Mar-26F
EBITDA	31,759	35,292	25,786	29,328	33,680
Cash Flow from Invt. & Assoc.					
Change In Working Capital	(6,645)	(604)	2,005	(551)	(1,185)
(Incr)/Decr in Total Provisions					
Other Non-Cash (Income)/Expense	(469)	(1,343)	1,554	8	9
Other Operating Cashflow	(6,445)	(7,357)	(6,993)	(8,521)	(10,452)
Net Interest (Paid)/Received	(1,159)	(2,048)	(1,834)	(1,708)	(1,708)
Tax Paid	4,016	5,077	4,788	5,489	6,455
Cashflow From Operations	21,057	29,017	25,307	24,046	26,798
Capex	(18,171)	(28,243)	(10,000)	(10,000)	(10,000)
Disposals Of FAs/subsidiaries					
Acq. Of Subsidiaries/investments					
Other Investing Cashflow	2,294	(1,371)			
Cash Flow From Investing	(15,877)	(29,614)	(10,000)	(10,000)	(10,000)
Debt Raised/(repaid)	1,472	6,599	(5,582)		
Proceeds From Issue Of Shares	2				
Shares Repurchased					
Dividends Paid	(2,117)	(2,133)	(1,899)	(1,899)	(1,899)
Preferred Dividends					
Other Financing Cashflow	(1,429)	(2,270)	(1,834)	(1,708)	(1,708)
Cash Flow From Financing	(2,073)	2,196	(9,315)	(3,607)	(3,607)
Total Cash Generated	3,107	1,599	5,991	10,439	13,191
Free Cashflow To Equity	6,652	6,002	9,724	14,046	16,798
Free Cashflow To Firm	6,339	1,451	17,140	15,754	18,506

SOURCE: INCRED RESEARCH, COMPANY REPORTS

Chemicals - Overall | India SRF Limited | December 11, 2023

BY THE NUMBERS...cont'd

(Rs mn)	Mar-22A	Mar-23A	Mar-24F	Mar-25F	Mar-26F
Total Cash And Equivalents	7,761	11,065	17,057	27,495	40,686
Total Debtors	17.925	17.856	16,242	16.732	17,789
Inventories	21,385	22,743	20,688	21,312	22,658
Total Other Current Assets	5,473	8,957	4,995	5,051	5,161
Total Current Assets	52,544	60,622	58,982	70,590	86,294
Fixed Assets	100,969	121,681	125,979	129,392	132,284
Total Investments	42	42	42	42	42
Intangible Assets					
Total Other Non-Current Assets	4,212	5,201	3,640	3,680	3,724
Total Non-current Assets	105,223	126,924	129,661	133,114	136,050
Short-term Debt	17,861	20,425	20,425	20,425	20,425
Current Portion of Long-Term Debt					
Total Creditors	20,964	22,313	20,296	20,908	22,229
Other Current Liabilities	5,579	6,428	2,818	2,825	2,832
Total Current Liabilities	44,403	49,166	43,540	44,159	45,487
Total Long-term Debt	17,533	23,115	17,533	17,533	17,533
Hybrid Debt - Debt Component					
Total Other Non-Current Liabilities	2,886	3,293	3,293	3,293	3,293
Total Non-current Liabilities	20,419	26,409	20,826	20,826	20,826
Total Provisions	7,290	8,700	8,694	8,742	8,794
Total Liabilities	72,113	84,275	73,060	73,727	75,107
Shareholders Equity	85,654	103,271	115,583	129,977	147,236
Minority Interests					
Total Equity	85,654	103,271	115,583	129,977	147,236
Key Ratios	Mar-22A	Mar-23A	Mar-24F	Mar-25F	Mar-26F
Revenue Growth	48.0%	19.6%	(9.0%)	3.0%	6.3%
Operating EBITDA Growth	48.0%	11.1%	(26.9%)	13.7%	14.8%
Operating EBITDA Margin	25.5%	23.7%	19.1%	21.0%	22.7%
Net Cash Per Share (Rs)	(93.23)	(109.57)	(70.52)	(35.30)	9.20
BVPS (Rs)	288.98	348.42	389.96	438.52	496.75
Gross Interest Cover	22.93	14.42	10.95	13.31	15.56
Effective Tax Rate	26.9%	23.4%	25.2%	25.2%	25.2%
Net Dividend Payout Ratio	8.8%	8.8%	13.4%	11.7%	9.9%
Accounts Receivables Days	45.02	43.91	46.01	43.19	42.53
Inventory Days	nm	nm	nm	nm	nm
Accounts Payables Days	nm	nm	nm	nm	nrr
ROIC (%)	21.5%	20.0%	13.5%	14.9%	17.0%
ROCE (%) Return On Average Assets	22.7%	20.9%	12.7%	13.5%	14.4%

SOURCE: INCRED RESEARCH, COMPANY REPORTS

DISCLAIMER

This report (including the views and opinions expressed therein, and the information comprised therein) has been prepared by Incred Research Services Private Ltd.(formerly known as Earnest Innovation Partners Private Limited) (hereinafter referred to as "IRSPL"). IRSPL is registered with SEBI as a Research Analyst vide Registration No. INH000011024. Pursuant to a trademark agreement, IRSPL has adopted "Incred Equities" as its trademark for use in this report.

The term "IRSPL" shall, unless the context otherwise requires, mean IRSPL and its affiliates, subsidiaries and related companies. This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject IRSPL and its affiliates/group companies to registration or licensing requirements within such jurisdictions.

This report is being supplied to you strictly on the basis that it will remain confidential. No part of this report may be (i) copied, photocopied, duplicated, stored or reproduced in any form by any means; or (ii) redistributed or passed on, directly or indirectly, to any other person in whole or in part, for any purpose without the prior written consent of IRSPL.

The information contained in this report is prepared from data believed to be correct and reliable at the time of issue of this report.

IRSPL is not required to issue regular reports on the subject matter of this report at any frequency and it may cease to do so or change the periodicity of reports at any time. IRSPL is not under any obligation to update this report in the event of a material change to the information contained in this report. IRSPL has not any and will not accept any, obligation to (i) check or ensure that the contents of this report remain current, reliable or relevant; (ii) ensure that the content of this report constitutes all the information a prospective investor may require; (iii) ensure the adequacy, accuracy, completeness, reliability or fairness of any views, opinions and information, and accordingly, IRSPL and its affiliates/group companies (and their respective directors, associates, connected persons and/or employees) shall not be liable in any manner whatsoever for any consequences (including but not limited to any direct, indirect or consequential losses, loss of profits and damages) of any reliance thereon or usage thereof.

Unless otherwise specified, this report is based upon reasonable sources. Such sources will, unless otherwise specified, for market data, be market data and prices available from the main stock exchange or market where the relevant security is listed, or, where appropriate, any other market. Information on the accounts and business of company(ies) will generally be based on published statements of the company(ies), information disseminated by regulatory information services, other publicly available information and information resulting from our research. Whilst every effort is made to ensure that statements of facts made in this report are accurate, all estimates, projections, forecasts, expressions of opinion and other subjective judgments contained in this report are based on assumptions considered to be reasonable as of the date of the document in which they are contained and must not be construed as a representation that the matters referred to therein will occur. Past performance is not a reliable indicator of future performance. The value of investments may go down as well as up and those investing may, depending on the investments in question, lose more than the initial investment. No report shall constitute an offer or an invitation by or on behalf of IRSPL and its affiliates/group companies to any person to buy or sell any investments.

The opinions expressed are based on information which are believed to be accurate and complete and obtained through reliable public or other nonconfidential sources at the time made. (Information barriers and other arrangements may be established where necessary to prevent conflicts of interests arising. However, the analyst(s) may receive compensation that is based on his/their coverage of company(ies) in the performance of his/their duties or the performance of his/their recommendations. In reviewing this report, an investor should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additional information is, subject to the duties of confidentiality, available on request. The report is not a "prospectus" as defined under Indian Law, including the Companies Act, 2013, and is not, and shall not be, approved by, or filed or registered with, any Indian regulator, including any Registrar of Companies in India, SEBI, any Indian stock exchange, or the Reserve Bank of India. No offer, or invitation to offer, or solicitation of subscription with respect to any such securities listed or proposed to be listed in India is being made, or intended to be made, to the public, or to any member or section of the public in India, through or pursuant to this report.

The research analysts, strategists or economists principally responsible for the preparation of this research report are segregated from the other activities of IRSPL. Information barriers and other arrangements have been established, as required, to prevent any conflicts of interests.

The research analysts, strategists or economists principally responsible for the preparation of this research report are segregated from the other activities of IRSPL. Information barriers and other arrangements have been established, as required, to prevent any conflicts of interests.

IRSPL may have issued other reports (based on technical analysis, event specific, short term views etc.) that are inconsistent with and reach different conclusion from the information presented in this report.

Holding of Analysts/Relatives of Analysts, IRSPL and Associates of IRSPL in the covered securities, as on the date of publishing of this report

InCred Equities

Chemicals - Overall | India SRF Limited | December 11, 2023

	Analyst/ Relative	Entity/ Associates
any financial interests in the company covered in this report (subject company) and nature of such financial interest	NO	NO
actual/beneficial ownership of 1% or more in securities of the subject company at the end of the month immediately preceding the date of publication of the research report or date of the public appearance;	NO	NO
any other material conflict of interest at the time of publication of the research report or at the time of public appearance	NO	NO
received any compensation from the subject company in the past twelve months for investment banking or merchant banking or brokerage services or investment advisory or depository or distribution from the subject company in the last twelve months for products/services other than investment banking or merchant banking or broker- age services or investment advisory or depository or distribution from he subject company in the last twelve months	NO	NO
nanaged or co-managed public offering of securities for the subject company in the last twelve months	NO	NO
received any compensation or other benefits from the subject company or third party in connection with the research report	NO	NO
served as an officer, director or employee of the subject company	NO	NO
been engaged in market making activity for the subject company	NO	NO

Analyst declaration

- The analyst responsible for the production of this report hereby certifies that the views expressed herein accurately and exclusively reflect his or her personal views and opinions about any and all of the issuers or securities analysed in this report and were prepared independently and autonomously in an unbiased manner.
- No part of the compensation of the analyst(s) was, is, or will be directly or indirectly related to the inclusion of specific recommendations(s) or view(s) in this report or based any specific investment banking transaction.
- The analyst(s) has(have) not had any serious disciplinary action taken against him/her(them).
- The analyst, strategist, or economist does not have any material conflict of interest at the time of publication of this report.
- The analyst(s) has(have) received compensation based upon various factors, including quality, accuracy and value of research, overall firm performance, client feedback and competitive factors.

IRSPL and/or its affiliates and/or its Directors/employees may own or have positions in securities of the company(ies) covered in this report or any securities related thereto and may from time to time add to or dispose of, or may be materially interested in, any such securities.

IRSPL and/or its affiliates and/or its Directors/employees may do and seek to do business with the company(ies) covered in this research report and may from time to time (a) buy/sell the securities covered in this report, from time to time and/or (b) act as market maker or have assumed an underwriting commitment in securities of such company(ies), and/or (c) may sell them to or buy them from customers on a principal basis and/or (d) may also perform or seek to perform significant investment banking, advisory, underwriting or placement services for or relating to such company(ies) and/or (e) solicit such investment, advisory or other services from any entity mentioned in thisreport and/or (f) act as a lender/borrower to such company and may earn brokerage or other compensation. However, Analysts are forbidden to acquire, on their own account or hold securities (physical or uncertificated, including derivatives) of companies in respect of which they are compiling and producing financial recommendations or in the result of which they play a key part.